Physician profile
Diana Case
NPI 1265481501
$2,597.91
in general payments reported to CMS, 2019-2025
17 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $744 · 2023: $837 · 2024: $565 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $391.86 | 2022 | |
| Abbott Laboratories | $273.66 | 2022-2023 | Proclaim |
| Novo Nordisk INC | $269.94 | 2023-2024 | Ozempic |
| Inari Medical, INC. | $168.75 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Si-Bone, INC. | $147.60 | 2023 | |
| Zimvie INC. | $144.41 | 2024 | |
| Nevro Corp. | $127.33 | 2024 | Senza |
| Astrazeneca Pharmaceuticals LP | $124.72 | 2022 | |
| Amgen INC. | $124.72 | 2023 | Otezla |
| Genzyme Corporation | $122.80 | 2025 | |
| Lilly USA, LLC | $116.15 | 2025 | Zepbound |
| Teva Pharmaceuticals USA, INC. | $112.34 | 2025 | Austedo Xr |
| Antares Pharma, INC. | $105.09 | 2023 | Tlando, Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $102.07 | 2022 | |
| Genentech USA, INC. | $100.38 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $87.61 | 2023 | |
| Merck Sharp & Dohme LLC | $78.48 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.